# Biosimilars Market

> Biosimilars Market Research Report: Size, Share, Trend Analysis By Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Bevacizumab, Trastuzumab, Ustekinumab, Tocilizumab, Aflibercept, Dupilumab, Denosumab, Others), Insulin, Granulocyte Colony- stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Anticoagulants, Others), By Applications (Oncology (Breast Cancer, Lung Cancer, Prostate Cancer, Leukemia, Bladder Cancer, Colorectal Cancer, Others), Autoimmune Diseases, Infectious Diseases, Blood Disorders, Others), by Route of Administration (Subcutaneous and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025-2035
- **CAGR:** 17.0%
- **2025:** USD 40.2 Billion
- **2035:** USD 193.2 Billion
- **Key Players:** Sandoz, Celltrion, Samsung Bioepis, Amgen, Pfizer, Biocon Biologics, Viatris, Fresenius Kabi

**Report ID:** MRFR/LS/0821-CR · **Pages:** 209 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/biosimilars-market-1329

---

## Market Summary

As per Market Research Future analysis, the Biosimilars Market Size was estimated at 36.79 USD Billion in 2024. The Biosimilar industry is projected to grow from 44.28 USD Billion in 2025 to 282.3 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 20.35% during the forecast period 2025 - 2035.
 
The Biosimilars Market is primarily driven by rising demand for cost-effective biologic alternatives and increasing healthcare expenditure, supported by patent expirations of major biologics and growing focus on improving treatment accessibility, enabling wider patient reach and sustainable healthcare systems globally.
 
According to the World Health Organization (WHO), biological therapies are essential for treating chronic diseases, while the Institute for Health Metrics and Evaluation (IHME) highlights increasing burden of cancer and autoimmune diseases, significantly driving demand for affordable biosimilar treatments worldwide.

## Market Drivers

## Driver Impact Analysis

| Driver | ~% Impact on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Biologic loss-of-exclusivity cliff | 4.6 | Global | Medium-term (2–4 yr) | [16] |
| Payer reimbursement reform | 3.4 | North America, EU | Short-term (≤2 yr) | [3] |
| Streamlined comparability pathways | 2.8 | Global | Medium-term (2–4 yr) | [1][2] |
| Single-use manufacturing economics | 2.3 | Asia-Pacific, EU | Long-term (≥4 yr) |   |
| National tender substitution mandates | 2.0 | Europe | Short-term (≤2 yr) | [12] |
| Oncology and immunology demand growth | 1.6 | Global | Long-term (≥4 yr) | [6] |
| Emerging-economy regulatory convergence | 1.2 | APAC, LATAM, MEA | Long-term (≥4 yr) | [18] |

### The Exclusivity Cliff Is Now the Sector's Clock

Reference products worth an estimated USD 180 billion in annual sales lose protection between 2026 and 2032, with pembrolizumab alone representing over USD 29 billion of that pool [[16]](https://evaluate.com). Every expiry converts a protected monopoly into a contested tender. The pattern from adalimumab is instructive: within 24 months of US entry, net prices fell 62% while volumes held, which grew total treated patients without growing spend.

### Reimbursement Turned From Obstacle to Accelerant

CMS now reimburses qualifying biosimilars at ASP plus 8% of the reference product's ASP under a five-year provision, reversing a decade-old provider disincentive [[3]](https://cms.gov). Medicare Part B biosimilar spending climbed 41% year over year in 2024. Germany's Rabattverträge and NHS England's commissioning framework produce the same effect through different mechanics, requiring switch programmes where clinical equivalence is established [[12]](https://england.nhs.uk).

### Regulators Removed the Redundant Clinical Step

Both the FDA and EMA have signalled that comparative efficacy studies are waivable when analytical and pharmacokinetic similarity is robust. The EMA's 2024 reflection paper formalised this, and the agency estimates it removes 18–30 months and up to USD 60 million from a typical programme [[2]](https://ema.europa.eu). Cutting that cost lowers the entry threshold for mid-tier developers.

### Manufacturing Intensity Rewrote the Cost Curve

Perfusion and intensified fed-batch systems have pushed monoclonal antibody titres from roughly 2 g/L to above 6 g/L over a decade, cutting cost of goods per gram by 55–70%. Single-use suites reach commercial output at one-third the capital of stainless-steel equivalents, which is why Asia-Pacific greenfield builds now dominate new capacity announcements.

## Restraints

## Restraints Impact Analysis

| Restraint | ~% Drag on CAGR | Geographic Relevance | Impact Timeline | Ref |
| --- | --- | --- | --- | --- |
| Rebate bundling by originators | 2.4 | North America | Short-term (≤2 yr) | [9] |
| Development cost and eight-year timelines | 1.9 | Global | Long-term (≥4 yr) | [7] |
| Price erosion compressing entrant returns | 1.7 | Europe | Medium-term (2–4 yr) | [12] |
| Patent thickets and litigation | 1.3 | North America | Medium-term (2–4 yr) | [17] |
| Prescriber and patient switching hesitancy | 0.9 | Global | Short-term (≤2 yr) | [6] |

### Rebate Walls Beat List Price

Originators protect share by bundling rebates across multi-product portfolios, so a formulary that adopts a lower-list biosimilar can lose more in aggregate rebate value than it saves. Analysis of US commercial plans found that reference-product net prices sat below several biosimilar net prices for two years post-entry [[9]](https://kff.org). Contract structure, not clinical evidence, determines placement.

### Capital Intensity Keeps Entrant Counts Low

A biosimilar programme runs USD 100–250 million and roughly eight years, against under USD 5 million for a small-molecule generic [[7]](https://rand.org). That barrier explains why most molecules attract three to six entrants rather than the twenty typical of oral generics. Where European tender prices have fallen 80% or more from the originator list, later entrants struggle to recover development spend at all.

## Opportunities

## Biosimilars Market Opportunities

### The Checkpoint Inhibitor Cohort

Pembrolizumab, nivolumab and atezolizumab collectively represent over USD 45 billion in annual revenue expiring between 2028 and 2032 [[16]](https://evaluate.com). Developers with high-titre capacity secured before 2028 will capture a disproportionate share of the resulting wave.

### Emerging-Market Regulatory Convergence

China, India, Brazil and Saudi Arabia have aligned abbreviated pathways to WHO guidance, allowing a single comparability package to serve multiple filings [[18]](https://nmpa.gov.cn). For exporters, this converts fragmented registration costs into a scalable regional strategy.

### Device-Led Differentiation

Autoinjectors, on-body delivery systems and citrate-free formulations now decide tenders where molecules are clinically equivalent. Subcutaneous conversion of intravenous oncology products opens a distinct premium tier within the Biosimilars Market.

### Real-World Evidence as a Commercial Asset

Switch-study registries and pharmacovigilance datasets have become licensable products, sold to payers modelling formulary transitions and to developers designing comparability protocols. Several European groups now monetise longitudinal switching cohorts covering more than 400,000 patient-years [[6]](https://amgen.com).

### Dedicated Contract Manufacturing

CDMO capacity above two million litres globally lets developers reach commercial scale without capital builds. Reserved-slot agreements have become a competitive weapon, particularly for firms targeting simultaneous multi-region launches.

## Future Outlook

## Biosimilars Market Future Outlook

### Analytics Replace Clinical Redundancy

Mass spectrometry, multi-attribute method platforms and machine-learning comparability models are displacing large efficacy trials. The EMA projects that analytics-led packages could cover most future submissions, removing 18–30 months per programme [[2]](https://ema.europa.eu). Development becomes a data problem rather than a recruitment problem.

### Platform Economics Reshape Competition

Winners will operate portfolio platforms — shared cell lines, shared analytics, shared regulatory infrastructure across ten or more molecules — rather than single-asset ventures. Marginal cost per additional programme on an established platform falls roughly 40%. That economics favours consolidation, and the Biosimilars Market will likely see fewer, larger participants by 2032.

### Subcutaneous Conversion Becomes the Value Layer

Converting infused oncology biologics to subcutaneous delivery shifts care out of infusion suites and cuts chair time by hours per patient. Health systems value that capacity release independently of drug price, creating a differentiation route that survives commoditisation [[6]](https://amgen.com).

### Access Economics Move Centre Stage

The WHO estimates that biologic affordability remains the binding constraint on cancer and autoimmune care across low- and middle-income settings, where per-course costs can exceed annual household income [[8]](https://who.int). Tiered pricing and regional manufacturing hubs will determine whether volume growth in these geographies materialises this decade.

## Segment Insights

## Biosimilars Market Segmentation

### By Product Class

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Monoclonal Antibodies | 54.6% share | Oncology and immunology expiries |
| Recombinant Hormones | USD 6.9 Billion | Fertility and growth indications |
| Insulin & Insulin Analogues | 19.8% CAGR | Interchangeability designations |
| Fusion Proteins & Anti-Inflammatory Agents | 11.3% share | Etanercept and aflibercept entries |
| Others | USD 2.1 Billion | Enzymes and anticoagulants |

Monoclonal antibodies dominate the Biosimilars Market because the largest reference products by revenue sit in this class, and because manufacturing platforms transfer readily between targets. Insulin is the more interesting story: US regulatory reclassification brought insulins under the biologics pathway, and pharmacy-level substitution has driven adoption faster than physician-administered products.

### By Indication

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Autoimmune & Chronic Inflammatory | 34.2% share | Adalimumab and ustekinumab cohorts |
| Oncology | 19.1% CAGR | Checkpoint inhibitor expiries |
| Blood Disorders | USD 6.4 Billion | Filgrastim and epoetin substitution |
| Diabetes | 12.7% share | Insulin biosimilar uptake |
| Growth Deficiency & Others | USD 3.3 Billion | Somatropin and fertility agents |

Autoimmune indications remain the revenue core of the Biosimilars Market, though price erosion there is now severe enough that volume growth outpaces value growth. Oncology carries the sharper trajectory, since the class expiring after 2028 is both high-value and clinically entrenched.

### By End User, Manufacturing Type and Route of Administration

| Segment | Metric (2025) | Primary Demand Driver |
| --- | --- | --- |
| Hospitals | USD 21.6 Billion | Infusion-administered biologics |
| Specialty Clinics | 21.7% CAGR | Outpatient oncology shift |
| Retail & Homecare | 14.9% share | Self-administered devices |
| In-House Manufacturing | 61.4% share | Vertically integrated developers |
| Contract Manufacturing | 22.9% CAGR | Capital-light entrant strategies |
| Intravenous | USD 23.1 Billion | Oncology infusion protocols |
| Sub-Cutaneous | 20.3% CAGR | Device conversion and homecare |

Hospitals still absorb the largest share of spending because infused products dominate current volumes. Specialty clinics grow faster as reimbursement follows patients into lower-cost outpatient settings, and subcutaneous formulations accelerate that migration.

## Regional Market Share Analysis

## Regional Market Share Analysis

| Region | Metric (2025) | Primary Investment Themes |
| --- | --- | --- |
| Europe | 38.5% share | Tender substitution, subcutaneous conversion |
| North America | USD 12.5 Billion | Reimbursement reform, interchangeability |
| Asia-Pacific | 21.4% CAGR | Domestic capacity, export registration |
| South America | 4.5% share | Public procurement, local partnering |
| Middle East & Africa | USD 1.4 Billion | Localisation mandates, access programmes |
| Total | USD 40.2 Billion | — |

Regional performance across the Biosimilars Market reflects three distinct policy models: tender-driven substitution in Europe, reimbursement-incentive design in North America, and domestic industrial policy across Asia-Pacific.

### North America

| Country | Metric | Key Driver |
| --- | --- | --- |
| US | 89.4% of region | Part B add-on uplift and interchangeability [3] |
| Canada | USD 1.02 Billion | Provincial switching policies [13] |
| Mexico | 17.6% CAGR | IMSS consolidated procurement [19] |

Canada's provincial biosimilar switching programmes, beginning with British Columbia and now covering nine provinces, mandated transition for established biologics and delivered documented savings exceeding CAD 1.1 billion cumulatively [[13]](https://cda-amc.ca). The US picture is more contested: adoption is strong in buy-and-bill Part B settings and weaker in pharmacy-benefit channels where rebate economics dominate.

### Europe

| Country | Metric | Key Driver |
| --- | --- | --- |
| Germany | 24.1% of region | Rabattverträge substitution quotas [12] |
| UK | USD 2.51 Billion | NHS commissioning framework [12] |
| France | 15.8% of region | Prescriber incentive scheme |
| Italy | USD 1.79 Billion | AIFA regional tenders |
| Spain | 9.4% of region | Hospital consortium purchasing |
| Nordic Countries | 22.8% CAGR | Single-winner national tenders |
| Russia | USD 0.61 Billion | Import substitution policy |
| Rest of Europe | 6.9% of region | EU centralised approval spillover |

Germany routes most biologic spend through sickness-fund rebate contracts, achieving substitution rates above 80% within 18 months for major molecules [[12]](https://england.nhs.uk). Nordic single-winner tenders deliver the deepest discounts in the world, sometimes exceeding 85% off originator list. Still, they concentrate national supply in one manufacturer and have twice triggered shortage contingency planning.

### Asia-Pacific

| Country | Metric | Key Driver |
| --- | --- | --- |
| China | 41.2% of region | NMPA volume-based procurement [18] |
| India | USD 1.94 Billion | CDSCO pathway and export scale [15] |
| Japan | 16.3% of region | MHLW target of 80% substitution [10] |
| South Korea | 24.6% CAGR | Celltrion and Samsung Bioepis exports |
| ASEAN | USD 0.51 Billion | ASEAN regulatory harmonisation |
| Rest of Asia-Pacific | 4.1% of region | Access programme expansion |

China's national volume-based procurement has extended from small molecules to biologics, with trastuzumab and bevacizumab rounds cutting prices 60–70% while multiplying volumes [[18]](https://nmpa.gov.cn). Korea occupies the opposite position: domestic consumption is modest, but Celltrion and Samsung Bioepis together supply a substantial share of European and US supply, making the country an export hub rather than a demand centre.

### South America

| Country | Metric | Key Driver |
| --- | --- | --- |
| Brazil | 62.8% of region | ANVISA pathway and PDP transfers [19] |
| Argentina | USD 0.29 Billion | Local manufacturing incentives |
| Rest of South America | 21.1% CAGR | Regional tender pooling |

Brazil's Productive Development Partnership model trades public purchase commitments for technology transfer, and has been applied to several biologics with Fiocruz and Bio-Manguinhos as anchors [[19]](https://gov.br/anvisa). The mechanism builds domestic capability but lengthens time to market, since transfer milestones gate procurement volumes.

### Middle East & Africa

| Country | Metric | Key Driver |
| --- | --- | --- |
| Saudi Arabia | 33.7% of region | Vision 2030 localisation mandate |
| UAE | USD 0.31 Billion | Federal formulary expansion |
| South Africa | 19.9% CAGR | SAHPRA registration reform |
| Egypt | USD 0.14 Billion | Universal health insurance rollout |
| Rest of MEA | 12.4% of region | Donor-funded access programmes |

Saudi Arabia's localisation policy grants procurement preference to products manufactured domestically, prompting joint ventures between Gulf investors and Asian developers [[20]](https://oecd.org). South Africa's regulator has cut median registration timelines materially since 2022, though oncology access still depends heavily on public-sector tender cycles.

## Competitive Benchmarking

## Competitive Benchmarking

Moderate concentrations. The estimated HHI is about 890, with the top five players accounting for 43-48% of worldwide sales. The structure at the molecular level is highly disparate: older filgrastim markets are populated by eight or more suppliers, whereas newer ustekinumab and denosumab cohorts remain three-to-five player battles. Asset-light licensors are becoming more distinguished from vertically integrated enterprises with owned capacity.

| Company | Est. Revenue Share Range | Key Offerings for Biosimilars Market | Strategic Positioning |
| --- | --- | --- | --- |
| Sandoz | ~11–14% | Immunology, oncology, hematology portfolio | Pure-play scale leader post-spinoff |
| Celltrion | ~9–12% | Infliximab, rituximab, ustekinumab, aflibercept | Integrated developer with owned capacity |
| Samsung Bioepis | ~8–11% | Immunology, ophthalmology, oncology | Manufacturing-linked, partner-distributed |
| Amgen | ~7–10% | Oncology and immunology biosimilars | Originator hedging its own franchises |
| Pfizer | ~6–9% | Oncology, inflammation, hematology | Broad portfolio, global commercial reach |
| Biocon Biologics | ~5–8% | Insulins, oncology, immunology | Cost-advantaged emerging-market base |
| Viatris | ~4–7% | Insulins, oncology, immunology | Distribution-led, partnership sourcing |
| Fresenius Kabi | ~3–6% | Immunology and oncology | Hospital-channel and IV expertise |
| Teva | ~2–5% | Oncology support, immunology | Selective in-licensing model |
| Coherus BioSciences | ~1–4% | Oncology support, ophthalmology | US-focused specialty commercial |
| Boehringer Ingelheim | ~1–4% | Adalimumab, ophthalmology | Interchangeability-first strategy |
| Dr. Reddy's Laboratories | ~1–3% | Oncology and hematology | Emerging-market and export focus |

## Recent News & Developments

## Recent News & Developments

- Sandoz (March 2025): Announced a USD 440 million biologics expansion in Slovenia to support its post-2027 launch pipeline, adding drug-substance and fill-finish capacity [[16]](https://evaluate.com).
- Celltrion (November 2024): Secured EU approval for its ustekinumab candidate, entering one of the largest immunology cohorts of the decade [[2]](https://ema.europa.eu).
- CMS (January 2024): Implemented the temporary ASP plus 8% add-on payment for qualifying biosimilars under Part B, materially improving provider economics in the Biosimilars Market [[3]](https://cms.gov).
- Samsung Bioepis (June 2025): Reported that its ophthalmology franchise reached blockbuster run-rate, validating device-differentiated entry in retinal indications [[16]](https://evaluate.com).
- Biocon Biologics (September 2024): Completed integration of the acquired global biosimilars business, consolidating commercial operations across 70 markets [[15]](https://biocon.com).
- EMA (July 2024): Published a reflection paper signalling that comparative efficacy trials may be waived where analytical and PK similarity is demonstrated [[2]](https://ema.europa.eu).
- NMPA (April 2025): Extended national volume-based procurement to additional monoclonal antibody categories, cutting awarded prices 60–70% [[18]](https://nmpa.gov.cn).
- Amgen (February 2025): Launched its denosumab biosimilars in the US following settlement of reference-product litigation [[17]](https://uspto.gov).

## Report Scope

| Attribute | Detail |
| --- | --- |
| Market Scope | Global development, manufacturing and commercialisation of approved biosimilar therapeutics |
| Study Period | 2021–2035 (Historical 2021–2024; Base Year 2025; Forecast 2026–2035) |
| CAGR (2026–2035) | 17.0% |
| Market Size Checkpoints | USD 40.2 Billion (2025); USD 47.0 Billion (2026); USD 103.1 Billion (2031); USD 193.2 Billion (2035) |
| Fastest Growing Segments | Insulin & Insulin Analogues; Oncology indication; Contract Manufacturing; Sub-Cutaneous route |
| Companies Profiled | 12 leading participants in the Biosimilars Market, plus 20 regional developers |
| Valuation Currency | USD, ex-manufacturer net realised revenue |

## Frequently Asked Questions

**Q: How do hospital procurement teams evaluate suppliers in the Biosimilars Market?**
A: Tenders weigh supply reliability, device usability and multi-year price stability more heavily than headline discount. Single-winner Nordic awards have cut prices sharply but concentrated national supply risk. Dual-sourcing clauses are now common. [12]

**Q: What separates biosimilar development economics from small-molecule generics?**
A: A biosimilar programme typically costs USD 100–250 million and runs about eight years, against under USD 5 million for a generic. That capital barrier keeps entrant counts per molecule in single digits. [7]

**Q: Does interchangeability designation guarantee pharmacy substitution?**
A: No. Substitution rules are set state by state in the US, and most require prescriber notification. Designation improves payer negotiating position more than it changes dispensed volume. [14]

**Q: How is contract manufacturing capacity shaping the Biosimilars Market?**
A: Dedicated CDMO capacity now exceeds two million litres globally, letting mid-tier developers skip capital builds entirely. Slot scarcity for high-titre mammalian lines remains the binding scheduling constraint through 2028. [11]

**Q: Why do rebate structures slow adoption despite lower list prices?**
A: Originators bundle rebates across product portfolios so that a lower-list biosimilar can cost formularies more in net terms. Several US payers have responded with mandatory-switch policies rather than renegotiating contracts. [9]

**Q: Which emerging-economy regulators matter most for the Biosimilars Market?**
A: China's NMPA, India's CDSCO and Brazil's ANVISA. All three now accept abbreviated comparative pathways aligned to WHO guidance, which reduces duplicate clinical work for exporters targeting multiple regions. [18]

**Q: How much do cold-chain and device costs affect delivered price?**
A: Cold-chain logistics and prefilled-device assembly can absorb 12–18% of total delivered cost. Device differentiation, rather than molecule quality, increasingly decides tender outcomes in the Biosimilars Market. [20]


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/biosimilars-market-1329*